Online Program Home
  My Program

Abstract Details

Activity Number: 243 - Contributed Poster Presentations: Biopharmaceutical Section
Type: Contributed
Date/Time: Monday, July 31, 2017 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #323876
Title: What Is the Best Design for Dose-Finding Trials with Small Number of Doses?
Author(s): Lai Wei* and Julie Stephens and Vedat Yildiz and Marilly Palettas and Songzhu Zhao and Xueliang Pan
Companies: and The Ohio State Univeristy and The Ohio State University and The Ohio State University and The Ohio State University and The Ohio State Univeristy
Keywords: dose-finding ; small number of doses ; phase I designs ; standard 3+3 design
Abstract:

Despite the development of innovative clinical trial designs, the standard 3+3 design continues to be the most common phase I dose finding trial design proposed by researchers to determine the optimal dose (MTD). Review criticisms of this design are increasing as awareness of the alternative designs grows. Unfortunately, as statisticians, it is sometimes difficult to convince the researcher to use the newer methods available. The goal of this study is to develop a persuasive argument to present to researchers to convince them to use a design other than the standard 3+3 design. The focus will be on trials with limited dose ranges (3-4 doses). Limited dose trials are common when an experimental drug is being tested in a new patient population or is being combined with other approved drugs. In this study, several phase I designs (standard 3+3, CRM, EWOC and BOIN) will be compared under various scenarios that preserve safety and maintain rapid accrual. Based on the simulation results, a "best" design, with minimal number of subjects being exposed to sub-therapeutic doses of the agent, will be recommended.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2017 program

 
 
Copyright © American Statistical Association